(1.03%) 5 070.03 points
(0.92%) 38 254 points
(1.63%) 15 860 points
(0.08%) $79.06
(5.75%) $2.04
(0.16%) $2 314.80
(0.70%) $26.94
(0.93%) $963.80
(-0.08%) $0.932
(-0.32%) $10.99
(-0.11%) $0.798
(-1.33%) $92.02
Quarter results today
(bmo 2024-05-02)
Expected move: +/- 11.83%
@ $29.86
Išleistas: 11 kov. 2024 @ 17:11
Grąža: -21.97%
Ankstesnis signalas: kov. 11 - 15:31
Ankstesnis signalas:
Grąža: -1.35 %
Live Chart Being Loaded With Signals
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency...
Stats | |
---|---|
Šios dienos apimtis | 814 336 |
Vidutinė apimtis | 1.48M |
Rinkos kapitalizacija | 2.25B |
EPS | $0 ( 2024-02-22 ) |
Kita pelno data | ( $-1.380 ) 2024-06-12 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.30 |
ATR14 | $0.0280 (0.12%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-10 | Dube Michael P | Sell | 0 | Common Stock |
2024-03-01 | Sepp-lorenzino Laura | Buy | 37 966 | Common Stock |
2024-03-01 | Sepp-lorenzino Laura | Buy | 54 794 | Stock Option (right to buy) |
2024-03-01 | Basta James | Buy | 32 394 | Common Stock |
2024-03-04 | Basta James | Sell | 2 297 | Common Stock |
INSIDER POWER |
---|
85.54 |
Last 100 transactions |
Buy: 1 561 723 | Sell: 123 854 |
Tūris Koreliacija
Intellia Therapeutics Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Intellia Therapeutics Inc Koreliacija - Valiuta/Žaliavos
Intellia Therapeutics Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $36.28M |
Bruto pelnas: | $27.30M (75.26 %) |
EPS: | $-5.42 |
FY | 2023 |
Pajamos: | $36.28M |
Bruto pelnas: | $27.30M (75.26 %) |
EPS: | $-5.42 |
FY | 2022 |
Pajamos: | $52.12M |
Bruto pelnas: | $44.55M (85.47 %) |
EPS: | $-6.37 |
FY | 2021 |
Pajamos: | $33.05M |
Bruto pelnas: | $33.05M (100.00 %) |
EPS: | $-3.78 |
Financial Reports:
No articles found.
Intellia Therapeutics Inc
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.